Edition:
United Kingdom

Cascadian Therapeutics Inc (CASC.OQ)

CASC.OQ on NASDAQ Stock Exchange Global Select Market

3.65USD
15 Dec 2017
Change (% chg)

$-0.04 (-1.08%)
Prev Close
$3.69
Open
$3.72
Day's High
$3.74
Day's Low
$3.63
Volume
987,500
Avg. Vol
87,860
52-wk High
$5.50
52-wk Low
$3.20

Select another date:

Wed, Nov 8 2017

BRIEF-Cascadian Therapeutics reports Q3 loss per share $0.28

* Cascadian Therapeutics reports third quarter 2017 financial results

BRIEF-Cascadian Therapeutics announces FDA orphan drug designation granted to Tucatinib for the treatment of HER2 colorectal cancer

* Cascadian Therapeutics announces FDA orphan drug designation granted to tucatinib for the treatment of HER2+ metastatic colorectal cancer Source text for Eikon: Further company coverage:

BRIEF-Cascadian Therapeutics Q2 loss per share $0.30

* Cascadian Therapeutics reports second quarter 2017 financial results

BRIEF-Cascadian Therapeutics announces positive regulatory update for Tucatinib in Europe

* Cascadian Therapeutics announces positive regulatory update for tucatinib in Europe

Select another date: